{"filing":{"accession_number":"0001628280-26-041543","cik":"0001894562","ticker":"PRME","company_name":"Prime Medicine, Inc.","form":"8-K","filing_date":"2026-06-08","report_date":null,"primary_document":"prme-20260605.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1894562/000162828026041543/prme-20260605.htm"},"events":[{"id":6341,"run_id":5555,"accession_number":"0001628280-26-041543","anchor_item_number":"5.07","event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.98,"summary":"This is a clear disclosure of shareholder vote results from Prime Medicine's June 5, 2026 annual meeting of stockholders. The filing reports voting outcomes for two proposals: (i) election of Michael Kelly and David Schenkein, M.D. as Class I Directors, and (ii) ratification of PricewaterhouseCoopers LLP as independent auditor. The detailed vote tallies (For, Against, Withheld, Abstentions, Broker Non-Votes) are presented in tabular form, which is the standard format for Item 5.07 disclosures. Director elections and auditor ratification are material governance matters affecting investor assessment of board composition and audit oversight.","company_name":"Prime Medicine, Inc.","ticker":"PRME","filing_date":"2026-06-08","form":"8-K","submitted_at":null,"items":[{"id":5204,"accession_number":"0001628280-26-041543","item_number":"5.07","item_title":"Submission of Matters to a Vote of Security Holders.","event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.98,"reasoning":"This is a clear disclosure of shareholder vote results from Prime Medicine's June 5, 2026 annual meeting of stockholders. The filing reports voting outcomes for two proposals: (i) election of Michael Kelly and David Schenkein, M.D. as Class I Directors, and (ii) ratification of PricewaterhouseCoopers LLP as independent auditor. The detailed vote tallies (For, Against, Withheld, Abstentions, Broker Non-Votes) are presented in tabular form, which is the standard format for Item 5.07 disclosures. Director elections and auditor ratification are material governance matters affecting investor assessment of board composition and audit oversight.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-08T20:12:18.790529+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":5204,"accession_number":"0001628280-26-041543","item_number":"5.07","item_title":"Submission of Matters to a Vote of Security Holders.","event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.98,"reasoning":"This is a clear disclosure of shareholder vote results from Prime Medicine's June 5, 2026 annual meeting of stockholders. The filing reports voting outcomes for two proposals: (i) election of Michael Kelly and David Schenkein, M.D. as Class I Directors, and (ii) ratification of PricewaterhouseCoopers LLP as independent auditor. The detailed vote tallies (For, Against, Withheld, Abstentions, Broker Non-Votes) are presented in tabular form, which is the standard format for Item 5.07 disclosures. Director elections and auditor ratification are material governance matters affecting investor assessment of board composition and audit oversight.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-08T20:12:18.790529+00:00","company_name":"Prime Medicine, Inc.","ticker":"PRME","filing_date":"2026-06-08"}]}